Changing economic outlooks will require monetary, fiscal or other issues, of course beyond what the market worries about more recently, lockdowns on a nearly-global basis, others (like Dr. Gottlieb) finally agreeing with my view for a few months that the emphasis needed to be on therapeutics not vaccines, a realization that finally has them calling on Regeneron (REGN) and others to ramp-up, it's fine and if Sorrento (SRNE) is able to join the effort, there's plenty of demand.
'In-theory'... 'if' Sorrento has the right MAB, aside the testing issue, they might win regardless who wins the Presidency or Congress. If Trump wins, the half baked herd immunity direction is a real (or dangerous) possibility. Very many people with weak immunity may need SRNE’s treatments to stay alive. And if Biden wins, he’ll want vaccines and treatments to be available before opening the Country, or at least not widely opening it. Using the flu vaccine as a guide, chances of a COVID vaccine eradicating COVID are slim. Sorrento treatments in theory would also be sought after in this scenario. So it’s a win-win for SRNE no matter who’s President. Providing of course no subterfuge holds things up.
The U.S. is trying to get through our own situation without mandatory or state imposed lockdowns, and the markets are sensitive to resultant economic data of course. In fact, aside the technical expectations of the recent shakeout, the market looks at economic metrics, and was stunned by the exponential gains of the coronavirus in Europe, where even countries previously doing a superb job were unable to contain it. And of course reopening too-swiftly was the key blame in all cases. That makes it hard for leaders in the U.S. to contradict.
|